| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| Targets |
STAT3
|
|---|---|
| ln Vivo |
Golotimod (SCV-07) hydrochloride, administered orally (oral gavage or subcutaneous injection, 100 μg/kg, 5 days), decreases experimental recurrent genital HSV-2 disease. Moreover, oral SCV-07 administered after fasting significantly lowers incidence and severity in female Hartley guinea pigs compared to SCV-07 administered without fasting[1]. In male LVG golden Syrian Hamsters, golotimod (SCV-07) hydrochloride (subcutaneous injection, once or twice a day, 100 μg/kg) can shorten the length of ulcerative OM and lessen the intensity and duration of acute and split radiation-induced oral mucositis (OM)[3].
|
| Animal Protocol |
Animal/Disease Models: Female Hartley guinea pigs (250-300 g) infected HSV-2[1]
Doses: 100 μg/kg Route of Administration: po (oral gavage) or subcutaneous (sc)injection; 5 days Experimental Results: diminished incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and demonstrated no significant reduction in disease by subcutaneous (sc)injection of SCV-07. Animal/Disease Models: Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis[3] Doses: 10, 100 μg/kg or 1 mg/kg Route of Administration: subcutaneous (sc)injection; once or twice a day from days 1 to 20 Experimental Results: demonstrated a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg. Dramatically diminished the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg. |
| References |
[1]. Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int J Antimicrob Agents. 2008 Sep;32(3):262-6.
[2]. Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May;56:84-92. [3]. Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Oral Dis. 2010 Oct;16(7):655-60. |
| Molecular Formula |
C16H20CLN3O5
|
|---|---|
| Molecular Weight |
369.80
|
| CAS # |
1029401-59-9
|
| Related CAS # |
Golotimod;229305-39-9;Golotimod TFA;2828433-07-2
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 150 mg/mL (405.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 20 mg/mL (54.08 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7042 mL | 13.5208 mL | 27.0416 mL | |
| 5 mM | 0.5408 mL | 2.7042 mL | 5.4083 mL | |
| 10 mM | 0.2704 mL | 1.3521 mL | 2.7042 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
